The SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI +1.09% closed at a five-year low of $64.37 on Monday as U.S. stocks plunged on concerns about continued inflation and the threat of weaker growth. The last time the price for the biotech ETF was down this low was in December 2018. "A combination of clinical and regulatory setbacks, lack of M&A, and macro environment has created a downward spiral that appears to us to be an excessive overreaction to the 2020- to early-'21 'bubble,'" RBC Capital Markets analyst Brian Abrahams told investors on Tuesday. The SPDR S&P Biotech ETF has tumbled 37.3% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +3.06% is down 16.2%.
new
Want to see how this story relates to your watchlist?
Just add items to create a watchlist now:
/zigman2/quotes/205950134/composite
Add to watchlist
/zigman2/quotes/210599714/realtime
Get news alerts on SPDR S&P Biotech ETF and S&P 500 Index — or create your own.
More News In
Industries
